Skip to main content
TLSI logo

TLSI · TriSalus Life Sciences, Inc. · Webcasts, Transcripts & Audio

Track TLSI — free
$4.15 -0.16 (-3.71%) At close · Oct 1
Market Cap
$267.23M
Shares
61.57M
Volume · Oct 1 273.18K Avg daily vol (3M) 288.7K

TriSalus Life Sciences, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for TriSalus Life Sciences, Inc. (TLSI), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-09-14
TriSalus Life Sciences, Inc. (TLSI) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-12
TriSalus Life Sciences, Inc. (TLSI) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript
Confident tone CMS G-code expanding reimbursement into OBL setting Quarterly revenue growth and commercial momentum PEDD platform and pressure-enabled drug delivery technology
Revenue
$11.41M
▲ 1.7% YoY
Diluted EPS
$-0.16
Gross margin
86.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
TriSalus Life Sciences, Inc. (TLSI) Q1 2026 Earnings Call Transcript
Positive tone Real-world evidence study / PEDD data New applications / market expansion Commercial organization expansion
Revenue
$8.90M
▼ 2.9% YoY
Diluted EPS
$0.03
Gross margin
86.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
Confident tone Commercial expansion / sales force New applications beyond liver Revenue growth and guidance
Revenue
$13.21M*
▲ 59.8% YoY
Gross margin
86.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
TriSalus Life Sciences, Inc. (TLSI) Q3 2025 Earnings Call Transcript
Confident tone TriNav platform expansion Genicular artery embolization (GAE) / knee osteoarthritis Revenue growth and guidance
Revenue
$11.57M
▲ 57.4% YoY
Diluted EPS
$-0.96
Gross margin
83.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript
Confident tone TriNav revenue growth and commercial momentum Nelitolimod partnership strategy TriNav FLX and product portfolio expansion
Revenue
$11.21M
▲ 52.3% YoY
Diluted EPS
$-0.27
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Call Transcript
Positive tone Liver embolization / TriNav adoption Nelitolimod and partnership strategy Product portfolio expansion
Revenue
$9.17M
▲ 42% YoY
Diluted EPS
$-0.39
Gross margin
83.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-11-14
TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript
Confident tone PERIO-03 pancreatic trial (nelitolimod) PROTECT registry for multinodular goiter (thyroid) Product launches (TriNav Large, TriGuide, TriNav 2.0)
Revenue
$7.35M
▲ 41.5% YoY
Diluted EPS
$-0.12
Gross margin
86.3%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-15
TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript
Confident tone Nelitolimod pipeline (PERIO trials) PEDD / TriNav technology differentiation Thyroid / PROTECT opportunity
Revenue
$7.36M
▲ 59.7% YoY
Diluted EPS
$-0.21
Gross margin
87.6%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-01
TriSalus Life Sciences, Inc. (TLSI) Q1 2024 Earnings Call Transcript
Confident tone Revenue growth and TriNav performance Reimbursement and clinical data for TriNav TriNav Large product launch
Revenue
$6.46M
▲ 116.4% YoY
Diluted EPS
$-0.60
Gross margin
85.0%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
TriSalus Life Sciences, Inc. (TLSI) Q4 2023 Earnings Call Transcript
Confident tone Revenue Growth and TriNav Sales Nelitolimod and Pancreatic Program Clinical Pipeline / PERIO Trials
Revenue
$5.72M*
Gross margin
89.8%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
TriSalus Life Sciences, Inc. (TLSI) Q3 2023 Earnings Call Transcript
Revenue
$5.19M
▲ 32.4% YoY
Diluted EPS
$-0.14
Gross margin
88.7%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–13 of 13 webcasts
Key facts CIK 1826667 CUSIP 89680M101 13F (30d) 1 filings 1 filers Visit website Investor relations